Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer

Nicolò Matteo Luca Battisti(Royal Marsden NHS Foundation Trust), Alistair Ring(National Health Service), Nishanthi Senthivel(Royal Marsden NHS Foundation Trust), Susan John(Royal Marsden NHS Foundation Trust), Vasileios Angelis(Royal Marsden NHS Foundation Trust), Stephanie Mappouridou(Royal Marsden NHS Foundation Trust), María Sol Andrés(Royal Brompton Hospital), Tamsin Nash(Royal Marsden NHS Foundation Trust), Elli‐Sophia Tripodaki(Royal Marsden NHS Foundation Trust), Kalaprapa Asavisanu(Royal Marsden NHS Foundation Trust), Sivatharshini Ramalingam(Royal Brompton & Harefield NHS Foundation Trust), Karla A. Lee(Royal Marsden NHS Foundation Trust), Alexander R. Lyon(Royal Brompton Hospital), E. Goode(Royal Marsden NHS Foundation Trust), Stuart D. Rosen(Royal Brompton & Harefield NHS Foundation Trust), Susannah Stanway(Royal Marsden NHS Foundation Trust), Emily Fleming(Royal Marsden NHS Foundation Trust), Mark Allen(Royal Marsden NHS Foundation Trust), Mariam Obeid(Royal Marsden NHS Foundation Trust)
Breast Cancer Research and Treatment
April 5, 2021
Cited by 74


Related Papers